%0 Journal Article
%A Mai, Elias K
%A Huhn, Stefanie
%A Miah, Kaya
%A Poos, Alexandra M
%A Scheid, Christof
%A Weisel, Katja C
%A Bertsch, Uta
%A Munder, Markus
%A Berlanga, Oscar
%A Hose, Dirk
%A Seckinger, Anja
%A Jauch, Anna
%A Blau, Igor W
%A Hänel, Mathias
%A Salwender, Hans J
%A Benner, Axel
%A Raab, Marc S
%A Goldschmidt, Hartmut
%A Weinhold, Niels
%T Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
%J Blood cancer journal
%V 13
%N 1
%@ 2044-5385
%C London [u.a.]
%I Nature Publishing Group
%M DKFZ-2023-00048
%P 1
%D 2023
%X Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) and performed a retrospective MS analysis at baseline (480 patients) and at the pre-defined, consecutive time points after induction (444 patients), prior to maintenance (305 patients) and after one year of maintenance (227 patients). We found that MS negativity was significantly associated with improved progression-free survival (PFS) even in patients with complete response (CR) at all investigated follow-up time points. The prognostic impact was independent of established risk factors, such as the revised International Staging System. Combining MS and baseline cytogenetics improved the prediction of outcome: MS-positive patients with high-risk cytogenetics had a dismal PFS of 1.9 years (95
%K Humans
%K Multiple Myeloma: therapy
%K Multiple Myeloma: drug therapy
%K Prognosis
%K Treatment Outcome
%K Retrospective Studies
%K Bone Marrow
%K Neoplasm, Residual: diagnosis
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:36599831
%2 pmc:PMC9812999
%R 10.1038/s41408-022-00772-9
%U https://inrepo02.dkfz.de/record/186679